Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.
Stockholm, 111 23
Founded in 2005
Bluefish Pharmaceuticals Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Fiscal 2015
May 21 15
Bluefish Pharmaceuticals announced earnings results for the first quarter of 2015. Net sales were SEK 70.8 million against SEK 44.5 million a year ago. EBITDA for the period, adjusted for currency effects, was SEK 2.8 million against loss of SEK 10.0 million a year ago. Basic loss per share amounted to SEK 0.06 against SEK 0.24 a year ago. Growth in net sales during the first quarter is, for the most part, due to the launch of existing products in new markets, primarily Spain, along with higher market share in established markets such as Sweden. The company has resulted in positive EBITDA of SEK 3.7 million for the period.
For the year 2015, net sales will fluctuate from quarter to quarter. However, the company expects net sales for the full year 2015 to increase compared to 2014. Growth originates from prior contracts, planned product launches and an overall increase in market share. Additionally, gross margin is expected to surpass last year's level.
Bluefish Pharmaceuticals AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2014
Feb 27 15
Bluefish Pharmaceuticals AB reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 60,271,000 compared to SEK 43,649,000 a year ago. Operating loss was SEK 6,444,000 compared to SEK 22,479,000 a year ago. Loss after financial items was SEK 7,569,000 compared to SEK 24,179,000 a year ago. Loss was SEK 7,569,000 or SEK 0.35 per share before and after dilution compared to SEK 24,701,000 or SEK 0.53 per share before and after dilution a year ago. LBITDA was SEK 1,446,000 compared to SEK 14,348,000 a year ago. Cash flow from operating activities was SEK 8,994,000 compared to SEK 13,270,000 a year ago.
For the year, on consolidated basis, the company reported net sales of SEK 187,748,000 compared to SEK 175,505,000 a year ago. Operating loss was SEK 56,102,000 compared to SEK 49,803,000 a year ago. Loss after financial items was SEK 61,377,000 compared to SEK 57,585,000 a year ago. Loss was SEK 62,519,000 or SEK 0.82 per share before and after dilution compared to SEK 58,494,000 or SEK 0.90 per share before and after dilution last year. LBITDA was SEK 34,109,000 compared to SEK 31,401,000 last year. Cash flow used in operating activities was SEK 25,632,000 compared to cash used in operating activities of SEK 29,363,000 a year ago.
For the quarter, on parent basis, the company reported net sales of SEK 57,259,000 compared to SEK 42,125,000 a year ago. Operating loss was SEK 7,447,000 compared to SEK 23,157,000 a year ago. Net loss was SEK 8,776,000 compared to SEK 26,230,000 a year ago.
For the year, on parent basis, the company reported net sales of SEK 185,148,000 compared to SEK 172,521,000 a year ago. Operating loss was SEK 54,217,000 compared to SEK 49,516,000 a year ago. Net loss was SEK 61,951,000 compared to SEK 58,707,000 last year.